PharmaLundensis AB is a Biotech company in Lund, Sweden, which develops new and unique treatments for the severe and common lung disease chronic obstructive pulmonary disease (COPD), based on a new mechanism of action. PharmaLundensis hypothesis is that COPD is caused by a lack of Epithelium Derived Relaxing Factor (EpDRF) from so called neuroepithelial endocrine cells in the airway epithelium, and that this is caused by inhalation of mercury from cigarette smoke. The lack of EpDRF leads to a strong and irreversible bronchial contraction, which, however, can be counteracted by intake of PharmaLundensis mercury binding substance IodoCarb®. Theoretically, it can be possible to CURE COPD by removing mercury from the patients, according to our hypothesis.
PharmaLundensis has developed a GMP certified test substance called IodoCarb®, which will be used during a placebo controlled Proof of concept study autumn 2011. In this study, the effect of IodoCarb® on the lung function and work capacity of 40 COPD patients will be evaluated. If this study is successful, PharmaLundensis plan to perform a Phase 2b clinical study during spring 2012, and a Phase 3study thereafter. If PharmaLundensis initial study is successful, we will seek Fast track status of the project from EMA (European Medical Agency). If everything goes according to plans, it is possible that IodoCarb® can be registered as a new COPD drug already during 2013.
There are also some other diseases that PharmaLundensis believe can be effectively treated by IodoCarb®. This will be further investigated in future clinical studies.
PharmaLundensis AB was founded in spring 2007 by Dr Staffan Skogvall, who stil works as CEO and Head of Research. The company is listed in “Aktietorget” and has some 500 shareholders.